Candriam S.C.A. Lowers Stake in Moderna, Inc. $MRNA

Key Points

• Candriam S.C.A. reduced its stake in Moderna, Inc. by 54.0% during the first quarter, holding approximately 281,946 shares valued at about $7.99 million after selling 330,916 shares.
• Moderna reported a quarterly loss of ($2.13) EPS, surpassing analysts' expectations while experiencing a 41.1% decrease in revenue compared to the previous year.
• Wall Street analysts have a consensus rating of "Hold" on Moderna, with an average price target of $43.59.

Candriam S.C.A. cut its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 54.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 281,946 shares of the company's stock after selling 330,916 shares during the quarter. Candriam S.C.A. owned approximately 0.07% of Moderna worth $7,993,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. S Bank Fund Management Ltd purchased a new position in Moderna in the 1st quarter valued at about $25,000. Itau Unibanco Holding S.A. raised its holdings in Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the last quarter. Costello Asset Management INC acquired a new stake in Moderna in the 1st quarter valued at about $30,000. Vega Investment Solutions acquired a new stake in Moderna in the 4th quarter valued at about $45,000. Finally, Sentry Investment Management LLC acquired a new stake in Moderna in the 1st quarter valued at about $31,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $26.22 on Friday. The company has a 50 day simple moving average of $29.17 and a 200-day simple moving average of $29.17. The company has a market capitalization of $10.20 billion, a P/E ratio of -3.48 and a beta of 1.83. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $86.80.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The business had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business's revenue was down 41.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. As a group, research analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of recent research reports. Cowen initiated coverage on shares of Moderna in a report on Sunday, July 13th. They issued a "hold" rating for the company. UBS Group cut their price objective on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a report on Friday, May 2nd. JPMorgan Chase & Co. set a $26.00 price objective on shares of Moderna in a report on Friday, August 1st. Morgan Stanley reiterated an "equal weight" rating and issued a $32.00 price objective on shares of Moderna in a report on Friday, August 1st. Finally, Citigroup initiated coverage on shares of Moderna in a report on Friday, August 1st. They issued a "neutral" rating and a $40.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, sixteen have issued a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $43.59.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.